Why does linaclotide cause diarrhea?

Diarrhea is the primary side effect because linaclotide increases chloride and bicarbonate secretion into the intestinal lumen via CFTR channels, drawing water into the bowel. This is the intended pharmacological effect. Most cases are mild to moderate and occur early in treatment. Severe diarrhea leading to dehydration is rare but requires discontinuation.

Is linaclotide absorbed into the bloodstream?

No. Linaclotide has minimal to no systemic absorption. It acts locally on GC-C receptors in the intestinal epithelium and is then degraded in the gut lumen. This local action avoids systemic side effects common to many drugs.

Treatment hubFDA ApprovedDeep Dive

Linaclotide Treatment Guide: Linzess, Constella, Cost and Provider Paths

In the United States, Linaclotide is an FDA-approved peptide therapy. Irritable bowel syndrome with constipation (IBS-C) in adults and children aged 6-17; chronic idiopathic constipation (CIC) in adults

Published: Apr 27, 2026Updated: Apr 27, 2026Medically reviewed: Apr 27, 2026Current

Medically Reviewed

This content was medically reviewed by Sarah Chen, MD, Board-Certified in Endocrinology, Diabetes, and Metabolism.

Last reviewed: April 27, 2026

Overview

Linaclotide is a guanylate cyclase-C (GC-C) receptor agonist approved by the FDA for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It increases intestinal fluid secretion and accelerates transit without being absorbed systemically.

Approved Product Paths

Linzess

Branded linaclotide pathway. Irritable bowel syndrome with constipation (IBS-C) in adults and children aged 6-17; chronic idiopathic constipation (CIC) in adults

Constella

Branded linaclotide pathway. Irritable bowel syndrome with constipation (IBS-C) in adults and children aged 6-17; chronic idiopathic constipation (CIC) in adults

Benefits

•Significant improvement in abdominal pain and bowel habits in IBS-C
•Increases complete spontaneous bowel movements in CIC
•Minimal systemic absorption (acts locally in gut)
•Approved for both adult and pediatric (6-17 years) IBS-C

Side Effects & Friction

•Diarrhea (most common; dose-dependent, usually early)
•Abdominal pain and distension
•Flatulence
•Headache

Administration Routes

Oral

Cost Reality

Linaclotide costs vary by brand, pharmacy, and insurance design. As an FDA-approved medication, coverage may be available but often requires prior authorization and documentation of the approved indication.

Provider Path

The highest-value next step is finding a provider experienced in anti-inflammatory who can evaluate whether Linaclotide fits the patient's clinical profile and insurance constraints.

How Linaclotide Works

Linaclotide is a 14-amino-acid peptide guanylate cyclase-C (GC-C) agonist. It acts locally in the intestinal lumen to increase fluid secretion and accelerate transit, reducing visceral hypersensitivity in irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Linaclotide binds to GC-C receptors on the luminal surface of intestinal epithelial cells. This activates the cystic fibrosis transmembrane conductance regulator (CFTR) and inhibits the sodium/hydrogen exchanger 3 (NHE3), increasing chloride and bicarbonate secretion and decreasing sodium absorption.

The net effect is increased intraluminal fluid, softer stools, and accelerated colonic transit. This mechanical effect is the primary mechanism in chronic constipation.

Separately, GC-C activation on intestinal epithelial cells produces extracellular cyclic GMP, which is transported to the submucosal space. There, cyclic GMP modulates activity of nociceptive afferent fibers, reducing visceral pain perception. This anti-nociceptive effect explains the improvement in abdominal pain in IBS-C independent of bowel movement frequency.

Linaclotide is minimally absorbed systemically (<0.1%). It acts locally in the gut and is degraded by intestinal proteases. Systemic side effects are therefore rare, though diarrhea can be significant.

The dual mechanism — secretory and anti-nociceptive — distinguishes linaclotide from simple osmotic or stimulant laxatives, which only increase stool water or motility without addressing visceral hypersensitivity.

Onset of bowel movement improvement is typically within 1 week. Abdominal pain improvement may take 2-4 weeks as visceral hypersensitivity gradually modulates.

Guanylate cyclase-C (GC-C)Intestinal epithelial cellsSubmucosal nociceptive afferents

Clinical Trial Evidence

IBS-C phase 3 trials (two identical trials)

Population: Adults with IBS-C (Rome III criteria)

N= 1,606

Duration: 26 weeks

Endpoint: Composite responder (≥30% reduction in abdominal pain AND increase ≥1 CSBM/week for ≥50% of weeks)

Responder rates: 33-34% vs 20-21% placebo (p<0.0001)
Abdominal pain reduced by ~40% in responders
Complete spontaneous bowel movements increased by 1.5-2 per week
Effect sustained throughout 26 weeks

CIC phase 3 trials

PMID: 23247223

Population: Adults with chronic idiopathic constipation

N= 1,272

Duration: 12 weeks

Endpoint: ≥3 complete spontaneous bowel movements per week and increase ≥1 from baseline for ≥9 of 12 weeks

Responder rates: 16-21% vs 3-6% placebo (p<0.001)
Stool consistency improved significantly
Straining and bloating scores reduced
Onset within first week

Dosing & Administration

IBS-C (Linzess)Oral · Once daily

Starting: 290 mcg once daily

Titration: No titration; fixed dose

Maintenance: 290 mcg once daily

Maximum: 290 mcg once daily

•Take on empty stomach at least 30 minutes before first meal
•Swallow capsule whole; do not crush or chew
•If missed, skip dose; do not double
•Not for patients ≤18 years (contraindicated due to dehydration risk)

CIC (Linzess)Oral · Once daily

Starting: 145 mcg once daily

Titration: May reduce to 72 mcg if 145 mcg not tolerated; may increase to 290 mcg if additional effect needed

Maintenance: 72-145 mcg once daily

Maximum: 290 mcg once daily

•Same administration as IBS-C dose
•Lower doses often sufficient for CIC
•Elderly patients may start at 72 mcg

Side Effect Profile

Very common

Diarrheamoderate16-20%

Most common side effect; dose-dependent; usually occurs within first 2 weeks; may lead to discontinuation in 5%

Abdominal painmild7%

Paradoxical; usually transient

Flatulencemild6%

Common

Headachemild5%

Mild

Serious

Severe diarrhea with dehydrationsevere<2%

Pediatric patients at particular risk; contraindicated in children

Contraindications & Warnings

Do Not Use

Pediatric patients ≤18 years (risk of severe dehydration)
Known or suspected mechanical GI obstruction
Hypersensitivity to linaclotide

Important Warnings

Pediatric warning: avoid in all patients ≤18 years. In neonatal mice, GC-C agonism caused severe dehydration and death. Clinical significance in older children unknown but contraindicated as precaution.
Diarrhea is common and may be severe. Patients should stop medication and rehydrate if severe diarrhea occurs. Dose reduction may help.
Not for use in mechanical bowel obstruction.
Pregnancy and lactation: limited data; theoretical risk of maternal dehydration affecting fetus.

Drug Interactions

Drug	Interaction	Severity	Mechanism
None significant	Minimal systemic absorption	minor	<0.1% systemic bioavailability; no CYP or transporter interactions

Monitoring Requirements

Bowel movement frequency and consistency
Abdominal pain scores
Signs of dehydration (orthostasis, dizziness, reduced urine output)
Weight (significant loss may indicate dehydration)
Electrolytes if severe diarrhea occurs

How Linaclotide Compares

MechanismLinaclotide advantage

Linaclotide: GC-C agonist (secretory + anti-nociceptive)

Lubiprostone (Amitiza): Chloride channel activator (secretory only)

Linaclotide has additional visceral analgesic effect

IBS-C efficacyLinaclotide advantage

Linaclotide: Responder rate 33-34%

Lubiprostone: Responder rate ~18%

Linaclotide more effective for IBS-C composite endpoint

EfficacyPlecanatide (Trulance) advantage

Linaclotide: Similar responder rates

Plecanatide (Trulance): Similar efficacy

Both GC-C agonists with comparable outcomes

Diarrhea ratePlecanatide advantage

Linaclotide: 16-20%

Plecanatide: 5-6%

Plecanatide has lower diarrhea discontinuation rate

CIC efficacyLinaclotide advantage

Linaclotide: Prescription; anti-nociceptive

Polyethylene glycol (Miralax): OTC osmotic laxative

Linaclotide superior for IBS-C; comparable for simple CIC

IBS-C efficacyLinaclotide advantage

Linaclotide: Consistent benefit

Dietary fiber: Variable; may worsen bloating

Fiber often poorly tolerated in IBS-C

Evidence Quality Assessment

Overall Evidence Grade: A

A = Strong evidence from multiple large RCTs

Human RCTs: Extensive: Large phase 3 trials for both IBS-C and CIC (total n>2,800)

Long-term data: Good: 26-week IBS-C data; open-label extension studies available

Real-world evidence: Extensive: Widely used since 2012 with favorable real-world tolerability

Regulatory status: FDA-approved for IBS-C and CIC in adults

Is Linaclotide Right for You?

Ideal Candidates

Adults with IBS-C who have failed dietary fiber and osmotic laxatives
Adults with CIC requiring prescription therapy
Patients with prominent abdominal pain component (benefits from anti-nociceptive effect)
Those preferring once-daily oral therapy

Avoid

Patients ≤18 years (contraindicated)
Suspected mechanical GI obstruction
Patients with severe chronic diarrhea
Pregnancy or breastfeeding (limited data)

Use With Caution

Elderly patients (start at lowest dose; dehydration risk)
Patients with renal impairment (dehydration may worsen)
Patients with cardiovascular disease (dehydration risk)
Those with occupations where urgent diarrhea would be problematic

Cost & Insurance Deep Dive

List Price (Monthly)

~$400-$500/month

Cash-Pay Range

$350-$500/month

Insurance Coverage Rate

~70-80% for IBS-C and CIC after step therapy

Prior Auth Likelihood

Moderate; often requires failure of fiber, PEG, or lubiprostone

Savings Programs

Linzess savings cardMay reduce copay to $30/month

Eligibility: Commercially insured

Not for government insurance

Patient assistanceFree for eligible patients

Eligibility: Uninsured, income ≤400% FPL

Annual application

Cost-Effectiveness Notes

•Cost-effective for IBS-C given dual pain and constipation benefit
•OTC alternatives (fiber, PEG) are far cheaper but less effective for IBS-C
•Generic competition expected in late 2020s
•Patient quality-of-life improvement justifies cost for refractory cases

Ready to find a linaclotide provider?

Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.

Find a linaclotide provider

Progress Tracking Tools

Monitor health markers and outcomes during treatment.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.

$10–20View on Amazon

Protein Shaker Bottle Set

Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.

$12–25View on Amazon

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Linaclotide FAQ

Sources

1. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Am J Gastroenterol • 2012
Claim type: clinical
View source →
2. FDA Information on Linaclotide
FDA • 2026
Claim type: regulatory
View source →

This content is for informational purposes only and does not constitute medical advice.